Article
Sep 10, 2025

Getting to Know GLP-1 Peptides

There’s been a lot of hype about GLP-1 peptides over the past few years due to their measurable success at helping people lose significant weight and reduce the biomarkers related to type-2 diabetes. 

This blog is a sneak peek from my new book, The Quantum Power of GLP-1 Peptides.

The body naturally produces glucagon-like peptides, which are made up of 30 amino acids, to aid in the digestion and absorption of the foods we eat, regulate appetite, manage blood sugar levels, and contribute to overall metabolic homeostasis. Considered to be both peptides and hormones, these powerful agents also exert control over cognitive functions, anxiety, and neurogenesis. 

Most GLP-1 peptides are produced by the ileum; they are produced in smaller amounts by the intestines and neurons in the brain. GLP-1s are released in response to eating to stimulate insulin secretion, slow digestion, reduce appetite, and make sure blood sugar levels are balanced. Together, these activities comprise the incretin system. 

Different forms of GLP-1s are produced in the body: 

  • GLP-1(7–36)-amide: A truncated form of GLP-1 that is secreted in response to eating
  • GLP-1(7–37): A truncated form of GLP-1 that is the biological precursor to GLP-1(7–36)-amide
  • GLP-1(1–37): A form of GLP-1 that has a lower insulinotropic efficacy than the truncated forms

As I’ve been discussing in Masterminds, courses, and other SSRP gatherings, people with chronic inflammation along with insulin resistance and/or type 2 diabetes have reduced metabolic functioning – they also suffer from an insufficiency in their incretin system and low levels of GLP-1 peptide production, which in turn triggers difficulty in managing blood sugar levels. 

And as we know, type 2 diabetes is closely associated with obesity, heart disease, cancer, and other metabolic disorders that compromise quality of life. 

How GLP-1s Work

GLP-1s work on several different molecular pathways, all of which support metabolism and redox homeostasis. Consider the figure below.

Signaling pathways activated by GLP-1 to promote beta cell mass expansion that supports overall cellular metabolism and redox balance

The Role of the Human Ileum in Gut Peptide Release

Before researchers identified GLP-1 receptor agonists and other gut peptides to address type-2 diabetes and weight loss, they were looking at the function of GLP-1 release in the body and its role in managing metabolism. Specifically, researchers discovered that the L cells found in the ileum, the final and longest part of the small intestine, release two important gut peptides: GLP-1 and peptide tyrosine tyrosine (PYY), both of which contribute to satiety and the regulation of appetite and food intake. 

It is the job of the L cells to secrete GLP-1s and PYY to stimulate insulin secretion from the pancreatic beta cells, inhibit glucagon release, and slow gastric emptying after a meal; we call this the ileal brake system, and it is at the heart of managing blood sugar, appetite, and metabolic efficiency. 

The L cells are stimulated by a range of metabolites, including dietary, microbial, and endogenous molecules to produce short-chain fatty acids (SCFAs). The ileum’s L cells also serve as sensing mechanisms; depending on the nature and degree of nutrients absorbed from food by the ileum, the L cells will release the gut peptides PYY and GLP-1. 

Interestingly, in a study published in 2024, researchers examined the dynamic, wide-ranging molecular environment in the intact human ileum and found that when plant-based foods with intact cellular structures are consumed, they can increase the delivery of nutrients to the ileum, which subsequently can lead to an increased release of satiety peptides (in particular, PYY). 

Of note, the researchers of this study discovered that the structure of the food sources did not impact the delivery of nutrients or the release of gut peptides. In other words, whether we ingest whole foods or break down our food into a liquid structure (as you’d do in a smoothie, for instance), the positive impact on the ileum and satiety is the same. The key player? Fiber. 

A Closer Look at the Role of L Cells

So, why this focus on L cells and the ileum? 

Under normal conditions (i.e., in the absence of insulin resistance, type 2 diabetes, or obesity), L cells have special protein and fatty acid receptors that help raise intracellular calcium levels, which in turn promote the release of GLP-1s. 

In addition, the binding of fatty acids to specific receptors also raises intracellular calcium levels. The now-elevated calcium levels promote exocytosis of GLP-1–containing vesicles, releasing GLP-1 into the circulation. (Note that proteins also promote GLP-1 release, but the mechanics are not yet fully understood.) 

Specifically, in the presence of sodium, L cells promote calcium influx by inducing depolarization; glucose also induces calcium influx by raising adenosine triphosphate (ATP) levels as a result of its catabolism. 

L cells have also been shown to express receptors for metabolic hormones, including insulin, leptin, and gastric inhibitory polypeptide (GIP). The degree to which leptin and insulin stimulate overall GLP-1 secretion is still unclear, but GIP-mediated GLP-1 release has been shown to occur in rodents via acetylcholine release by the enteric nervous system. Supraphysiological concentrations of GIP can also activate GIP receptors on L cells, potentially enhancing GLP-1 secretion. 

The figure below is a visual depiction of the importance of L cells.

Keep in mind how and why L cells produce GLP-1s

The L cell mechanism related to GLP-1 release underscores the different factors related to metabolic homeostasis. In particular, L cells help coordinate glucose metabolism, appetite regulation, and insulin secretion. Once released, GLP-1 enhances insulin secretion from pancreatic beta cells (in a glucose-dependent manner) and improves postprandial glucose control while suppressing glucagon release to prevent unnecessary glucose production. Additionally, GLP-1 slows gastric emptying, reducing the rate of nutrient absorption and promoting satiety, which helps regulate energy balance and prevent overeating. Beyond these immediate metabolic effects, GLP-1 also influences lipid metabolism, inflammation, and cardiovascular health, contributing to overall metabolic stability. 

In Part X, when we dig into the specific GLP-1 RA peptides, keep in mind how the body’s innate GLP-1 release begins as a response to both the foods we eat and the state of our microbiome. In the next section, we will look at how the health of our microbiome can contribute to metabolic flexibility . . . or its degradation.

Taken from The Quantum Power of GLP-1 Peptides.

RELATED RESOURCES

Continue exploring related topics.

VIEW ALL
ARTICLE
Scott Sherr, MD
Jul 2, 2026
Methylene Blue: From Cellular Energy to Clinical Practice
Scott Sherr, MD Jul 2, 2026
Methylene Blue: From Cellular Energy to Clinical Practice
Scott Sherr, MD | Lucía González Forte, PhD  Submitted for publication [Article] to the SSRP Institute Abstract Methylene blue (MB) is a century-old compound whose renewed relevance in clinical medicine reflects a clearer understanding of its role in mitochondrial function, redox biology, and neuroinflammatory signaling. At therapeutic oral doses, MB acts as a catalytic electron […]
READ ARTICLE
Foundational Foundational
The Self-Led Woman
If you are in midlife and feel like your body stopped following the rules it used to, this course is for you. The premise is simple: your body is not broken. It is running a different program than the one...
9 Lessons
1 Hour 28 Minutes
View Course
VIDEO
Cellular Medicine Mondays
Jun 29, 2026
Ep. 094 - Cellular Optimization for EDS Surgical Support
Preview Only
Dissecting Protocols – Episode 094

Cellular Optimization for EDS Surgical Support

Dr. Seeds reviews peptide and supplemental considerations for cellular optimization in an EDS patient preparing for orthopedic surgery. (Question Link)

Preview Only — Become a member for full access
VIDEO
Cellular Medicine Mondays
Jun 22, 2026
Ep. 093 - The Phosphatidylcholine Pathway
Preview Only
Rabbit Holes – Episode 093

The Phosphatidylcholine Pathway

Dr. Seeds expands on Journal Club Episode 92 to explore the role of phosphatidylcholine in lipid metabolism, methylation, and mitochondrial integrity during aging. He also highlights how estrogen loss may impact this pathway, especially in pre- and post-menopausal women.

Preview Only — Become a member for full access
Pathways Pathways
The Cell Code
A Cellular Medicine Perspective on Health, Aging, and Disease Cell Code is a structured walk through ten core molecular pathways that shape Cellular Medicine. For each pathway, the course presents twenty questions, beginning with foundational mechanisms and moving into applied...
31 Lessons
Self-paced
View Course
VIDEO
Cellular Medicine Mondays
Jun 15, 2026
Ep. 092 - Aging-Associated Decline of Phosphatidylcholine Synthesis is a Malleable Trigger of Natural Mitochondrial Aging
Preview Only
Journal Club – Episode 092

Aging-Associated Decline of Phosphatidylcholine Synthesis is a Malleable Trigger of Natural Mitochondrial Aging

Dr. Seeds explores how age-related decline in phosphatidylcholine synthesis may contribute to mitochondrial aging and why that matters in Cellular Medicine. This discussion connects membrane integrity, mitochondrial function, methylation, and metabolic resilience, while highlighting how this pathway may be more modifiable than we once thought.

Preview Only — Become a member for full access
SSRP Institute Jun 10, 2026
PCOS Name Change to PMOS: Polyendocrine Metabolic Ovarian Syndrome
HEADLINE SCIENCE An international body of medical scientists in obstetrics and gynecology, endocrinology, and other speciality societies, and other physicians announced the result of a multi-year process to formally change the name of Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change, published in May 2026 in The Lancet, aims to address […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Jun 8, 2026
Ep. 091 - Dr. Seeds’ Office Hours
Preview Only
ARTICLE
William Seeds, MD
Jun 3, 2026
GLP-1 and the Gut–Musculoskeletal Axis: A Clinical Summary
William Seeds, MD Jun 3, 2026
GLP-1 and the Gut–Musculoskeletal Axis: A Clinical Summary
The Overlooked Connection: Dysbiosis and Degenerative Disease Degenerative musculoskeletal diseases, including osteoarthritis (OA), osteoporosis (OP), sarcopenia (SP), and intervertebral disc degeneration (IVDD), affect well over a billion people globally and share three core pathological features: chronic inflammation, oxidative stress, and dysregulated cell death. What is increasingly clear, and clinically underappreciated, is that gut microbiota (GM) […]
READ ARTICLE
Certification
Peptide Therapy Certification 2026
Clinical peptides are proving to be an increasingly impactful tool in a physician’s patient care toolkit. With wide-ranging applicability across cardiology, pediatrics, fertility, orthopaedics, and more, peptide therapy can help you deliver more individualized care and create better outcomes for...
REGISTER NOW

Subscribe to the SSRP Community Digest

Get the latest research and developments in the field of Cellular Medicine straight to your inbox every month.

This field is for validation purposes and should be left unchanged.